Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
Daiichi Sankyo suffered a hefty sales plunge of its major hypertension drug Olmetec (olmesartan), particularly in the US, with its FY2017 group revenue up only 0.5% to 960 billion yen, which actually translates into a year-on-year decline of 8.9 billion…
To read the full story
Related Article
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda’s Takeover Bid for Shire “Thought-Provoking”: Daiichi Sankyo CEO
May 1, 2018
- Despite Upbeat AGs, Daiichi Sankyo to Closely Watch Pricing Environment: CEO
May 1, 2018
- Daiichi Sankyo to Announce “Important Measures” to Shore Up Biz by 2nd Qtr Earnings
May 1, 2018
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
May 12, 2017
BUSINESS
- Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
- Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
- Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
- Chugai’s Hemlibra Successor Shows Promise in PI/II Study
February 10, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…